Trop2-targeted therapies in solid tumors: advances and future directions

By Xin-long Liu, Leina Ma, Jiyixuan Li, Li Sun, Ying Yang, Ting Liu, Dongming Xing, Saisai Yan, Miao Zhang. 2024

Subfields: Oncology, Pharmacology

Citations in the corpus

• A Phase II study of SHR-A1921, a TROP2-targeted antibody–drug conjugate, in patients with recurrent or metastatic salivary gland carcinoma (2026, unknown): “Although cross-study comparisons must be interpreted with caution due to differences in study design, patient populations, dosing regimens, ADC constructs, and tumor subtypes, SHR-A1921 ’ s mucosal tolerability showed a higher oral mucositis incidence than in related indications with other TROP2-tar”